X4 Pharmaceuticals, Inc.
XFOR
$0.21
-$0.0016-0.76%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 156.07% | -0.53% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 156.07% | -0.53% | |||
| Cost of Revenue | 33.04% | -15.30% | |||
| Gross Profit | 239.94% | 12.88% | |||
| SG&A Expenses | -3.29% | 17.94% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.96% | 1.74% | |||
| Operating Income | -3.52% | -1.78% | |||
| Income Before Tax | -7.86% | -140.37% | |||
| Income Tax Expenses | 1,620.00% | -16.67% | |||
| Earnings from Continuing Operations | -8.52% | -140.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.52% | -140.40% | |||
| EBIT | -3.52% | -1.78% | |||
| EBITDA | -3.53% | -1.57% | |||
| EPS Basic | -7.39% | -140.31% | |||
| Normalized Basic EPS | -6.75% | -158.73% | |||
| EPS Diluted | -7.39% | -140.60% | |||
| Normalized Diluted EPS | -6.75% | -159.32% | |||
| Average Basic Shares Outstanding | 1.03% | 0.21% | |||
| Average Diluted Shares Outstanding | 1.03% | 0.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
